VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 445.2 USD | +1.04% |
|
+5.31% | +9.42% |
| May. 15 | Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director | CI |
| May. 14 | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 10.75B | Sales 2025 * | 11.67B | Capitalization | 115B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.99B | Net income 2025 * | 4.46B | EV / Sales 2024 * | 9.39 x |
| Net cash position 2024 * | 13.97B | Net cash position 2025 * | 19.01B | EV / Sales 2025 * | 8.21 x |
| P/E ratio 2024 * |
29.3
x | P/E ratio 2025 * |
26
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | +1.04% | ||
| 1 week | +5.31% | ||
| Current month | +13.34% | ||
| 1 month | +13.26% | ||
| 3 months | +5.45% | ||
| 6 months | +27.02% | ||
| Current year | +9.42% |
1 week
422.44
446.10
1 month
391.25446.10
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
165.23448.40
10 years
63.68448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 445.2 | +1.04% | 1,382,490 |
| 24-05-16 | 440.6 | +0.72% | 1,215,998 |
| 24-05-15 | 437.5 | +2.08% | 1,059,443 |
| 24-05-14 | 428.6 | -0.31% | 935,891 |
| 24-05-13 | 429.9 | +1.69% | 939,753 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B | |
| -24.95% | 8.23B |
- Stock Market
- Equities
- VRTX Stock
